Abeona Therapeutics (NASDAQ:ABEO) CEO Vishwas Seshadri Sells 19,274 Shares

Abeona Therapeutics Inc. (NASDAQ:ABEO) CEO Vishwas Seshadri sold 19,274 shares of the stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $5.39, for a total transaction of $103,886.86. Following the sale, the chief executive officer owned 1,215,067 shares in the company, valued at approximately $6,549,211.13. This trade represents a 1.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Vishwas Seshadri also recently made the following trade(s):

• On Tuesday, September 30th, Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.24, for a total transaction of $131,000.00.
• On Wednesday, July 9th, Vishwas Seshadri sold 69,420 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.86, for a total transaction of $406,801.20.

Abeona Therapeutics Price Performance

NASDAQ ABEO opened at $5.41 on Friday. Abeona Therapeutics Inc. has a 52 week low of $3.93 and a 52 week high of $7.54. The company has a current ratio of 6.73, a quick ratio of 6.65 and a debt-to-equity ratio of 0.09. The stock has a market cap of $277.42 million, a price-to-earnings ratio of 7.73 and a beta of 1.42. The company has a 50-day moving average price of $6.36 and a two-hundred day moving average price of $5.92.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Thursday, August 14th. The biopharmaceutical company reported $1.71 EPS for the quarter, topping the consensus estimate of ($0.39) by $2.10. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $21.71 million. Analysts forecast that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ABEO shares. Oppenheimer increased their price objective on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Friday, August 15th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Abeona Therapeutics in a report on Saturday, September 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a report on Monday, August 18th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

Institutional Trading of Abeona Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Corient Private Wealth LLC bought a new stake in Abeona Therapeutics during the second quarter worth approximately $127,000. Squarepoint Ops LLC lifted its position in shares of Abeona Therapeutics by 274.2% in the 2nd quarter. Squarepoint Ops LLC now owns 141,978 shares of the biopharmaceutical company’s stock valued at $806,000 after acquiring an additional 104,037 shares in the last quarter. Man Group plc purchased a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at approximately $67,000. BNP Paribas Financial Markets purchased a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at approximately $749,000. Finally, Boone Capital Management LLC purchased a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at approximately $7,126,000. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.